Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma

April, 05, 2014 : Bharat Book Bureau presents the new report, on "Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma". I2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations.

2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. The implications of new price-reversions are going to have many facets and will change conventional business models. We expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer. We also expect consolidation and M&A activities to spur in Japan.

Innovation Takes the Driver's Seat: While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'. Japanese innovators will now become more serious and selective in their R&D approach. Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5). We expect this trend to prevail in the coming years. We find some of the candidates to remain in the limelight in 2014 along with some new additions - Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them. The reports explain detail analysis on these key candidates.

The 138 pages report contains the detailed discussion of Japan biopharmaceutical market – which includes- Our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in domestic Japan market etc…) of leading Japanese innovator companies- Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Kyorin, Kyowa hakko Kirin, Mitsubishi Tanabe, Shionogi, Takeda and leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.

-New Price-Cuts – A Double Punch To The Innovators!
-New Slabs For Nhi Price Cuts For Long-listed Drugs
-Expense Vs. Protability Of Japanese Innovators
-Another Blow For Innovators In Not Institutionalizing The ‘Innovation Premium’

Pressure To Generic Discount Further Increased
Upcoming New Generics
Existing Generics
New Drug Prices For Existing Ge Drugs
Listing Of GE Drugs by Both GE Name And Brand To Promote Discounting

Finding New Avenues Of Cost Saving Are Inevitable For GE Cos
Innovators Need To Redene Long-Listed Products Strategies
Consolidation Activities To Will Witness A Boost

For more information kindly visit : 

Related Reports : 

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
For live chat :
Follow us on twitter: 
Follow us on linkedin : 
Our Blog : 

About Author Bio: I am working with a market research company which provides market research reports , company profiles, custom research, industry analysis, country reports , business reports, online databases and the report on "Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma" etc. Through our industry analysis you can identify opportunities, analyze the requirements of the customers and study the competition sector wise.